John H Alexander, Richard C Becker, Deepak L Bhatt, Frank Cools, Filippo Crea, Mikael Dellborg, Keith A A Fox, Shaun G Goodman, Robert A Harrington, Kurt Huber, Steen Husted, Basil S Lewis, Jose Lopez-Sendon, Puneet Mohan, Gilles Montalescot, Mikhail Ruda, Witold Ruzyllo, Freek Verheugt, Lars Wallentin
BACKGROUND: After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding. METHODS AND RESULTS: Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) was a phase 2, double-blind, placebo-controlled, dose-ranging study. Patients (n=1715) with recent ST-elevation or non-ST-elevation acute coronary syndrome were randomized to 6 months of placebo (n=611) or 1 of 4 doses of apixaban: 2...
June 9, 2009: Circulation